Endometrial Adenocarcinoma Clinical Trial
Official title:
Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy
NCT number | NCT03164590 |
Other study ID # | 388 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | June 1, 2017 |
Est. completion date | September 1, 2018 |
Verified date | January 2018 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to compare the effects of local wound infiltration with ketamine versus dexmedetomidine when added to bupivacaine on inflammatory cytokine response after total abdominal hysterectomy.
Status | Completed |
Enrollment | 60 |
Est. completion date | September 1, 2018 |
Est. primary completion date | August 1, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - ASA I-II patients - age range (18-60) years, - weight (50- 90) kg Exclusion Criteria: - allergy to study drugs - significant cardiac disease - respiratory disease - renal disease - hepatic disease |
Country | Name | City | State |
---|---|---|---|
Egypt | South Egypt Cancer instIitute | Assuit |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Egypt,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | severity of pain at rest and on coughing | severity of pain at rest and on coughing will be assessed using a 10-cm Visual Analog Scale (0 = no pain and 10 = worst imaginable pain) | 24 hours | |
Secondary | sedation | sedation by using sedation score | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01935973 -
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03660826 -
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
|
Phase 2 | |
Active, not recruiting |
NCT04106414 -
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
|
Phase 2 | |
Completed |
NCT01642082 -
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01208467 -
Prognostic Biomarkers in Patients With Endometrial Cancer
|
N/A | |
Completed |
NCT01011933 -
Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT00025467 -
Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01440998 -
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
|
Phase 1 | |
Completed |
NCT00006089 -
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00977574 -
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Completed |
NCT01968317 -
Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
|
Phase 2 | |
Completed |
NCT01225887 -
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01005329 -
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02208375 -
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
|
Phase 1/Phase 2 | |
Completed |
NCT03716414 -
Evaluation of the Efficacy for Sentinel Lymph Node Policy in High-risk Endometrial Carcinoma
|
||
Withdrawn |
NCT03836157 -
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06399757 -
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00095979 -
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT00072176 -
Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
|
Phase 2 |